The abstract is read at the publisher; the summary is JClub's.
In an international retrospective cohort of 1174 biopsy-proven Erdheim-Chester disease patients, 261 (22%) died after a median 49 months, with older age and treatment non-response linked to higher mortality.
- Why it matters: Erdheim-Chester disease has heterogeneous presentation and limited natural-history and prognosis data, creating a need to identify clinical features that predict survival and guide risk-adapted care.
- What they did: Investigators in 10 countries collected standardized referral-centre data on patients diagnosed 1985–2024, including those with at least 6 months follow-up; multivariable Cox regression assessed mortality predictors.
- The result: Independent mortality predictors were older age (p<0·0001), neurodegeneration (HR 4·2, 95% CI 2·4–7·1; p<0·0001), high C-reactive protein (3·8, 1·6–9·1; p=0·0022), second haematological cancer (3·0, 1·5–6·0; p=0·0023), and no response to treatment (2·8, 1·6–5·1; p=0·0006).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.